A modeling and simulation approach to characterize methadone QT prolongation using pooled data from five clinical trials in MMT patients

Clinical Pharmacology and Therapeutics

Volumn 91, Issue 4, 2012, Pages 666-672

  Florian, J ^a   Garnett, C E ^a   Nallani, S C ^a   Rappaport, B A ^b   Throckmorton, D C ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b Center for Drug Evaluation and Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHADONE;

ADULT; ARTICLE; CARDIOVASCULAR RISK; ELECTROCARDIOGRAM; FEMALE; HEART RATE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; PREDICTIVE VALUE; PRIORITY JOURNAL; QT PROLONGATION; TIME TO MAXIMUM PLASMA CONCENTRATION; TORSADE DES POINTES;

ADULT; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LONG QT SYNDROME; MALE; METHADONE; MIDDLE AGED; MODELS, BIOLOGICAL; OPIOID-RELATED DISORDERS; PROSPECTIVE STUDIES;

EID: 84858798099     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.273     Document Type: Article

References (47)

1. Gardner-Nix, J.S. Oral methadone for managing chronic nonmalignant pain. J. Pain Symptom Manage. 11, 321-328 (1996). (Pubitemid 26129967)
2. Pearson, E.C. & Woosley, R.L. QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system. Pharmacoepidemiol. Drug Saf. 14, 747-753 (2005). (Pubitemid 41684467)
3. Callahan, R.J., Au, J.D., Paul, M., Liu, C. & Yost, C.S. Functional inhibition by methadone of N-methyl-D-aspartate receptors expressed in Xenopus oocytes: stereospecific and subunit effects. Anesth. Analg. 98, 653-659, table of contents (2004). (Pubitemid 38252653)
4. Katchman, A.N. et al. Influence of opioid agonists on cardiac human ether-a-gogo-related gene K(+) currents. J. Pharmacol. Exp. Ther. 303, 688-694 (2002). (Pubitemid 35231242)
5. Ehret, G.B. et al. Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors. Arch. Intern. Med. 166, 1280-1287 (2006). (Pubitemid 43967579)
6. George, S. Methadone-associated QT prolongation and torsades de pointes. Br. J. Hosp. Med. (Lond). 68, 221 (2007).
7. Iskandar, S.B., Jordan, R.M. & Peiris, A.N. Electrocardiographic abnormalities and endocrine diseases-part c: parathyroid, hypothalamus and pituitary glands. Tenn. Med. 100, 43-44 (2007).
8. Kornick, C.A. et al. QTc interval prolongation associated with intravenous methadone. Pain 105, 499-506 (2003). (Pubitemid 37186911)
9. Krantz, M.J., Lewkowiez, L., Hays, H., Woodroffe, M.A., Robertson, A.D. & Mehler, P.S. Torsade de pointes associated with very-high-dose methadone. Ann. Intern. Med. 137, 501-504 (2002). (Pubitemid 35024621)
10. Lucchini, A., Barbaro, G. & Barbarini, G. Methadone and QT prolongation in HIV-infected patients. Am. J. Cardiol. 94, 147-148 (2004). (Pubitemid 38813477)
11. Martell, B.A., Arnsten, J.H., Krantz, M.J. & Gourevitch, M.N. Impact of methadone treatment on cardiac repolarization and conduction in opioid users. Am. J. Cardiol. 95, 915-918 (2005). (Pubitemid 40386816)
12. Schmittner, J. & Krantz, M.J. High-dose methadone and QTc prolongation: strategies to optimize safety. J. Opioid Manag. 2, 49-55 (2006).
13. Schmittner, J. & Krantz, M.J. QTc prolongation among hospitalized patients receiving methadone. Arch. Intern. Med. 166, 2289; author reply 2289-2290 (2006). (Pubitemid 44748785)
14. US Food and Drug Administration. Dolophine hydrochloride package insert (2006).
15. US Food and Drug Administration. Methadose oral concentrate (methadone HCL) package insert (2008).
16. Substance Abuse and Mental Health Services Administration. Methadone-Associated Mortality: Report of a National Assessment (2007).
17. Krantz, M.J., Martin, J., Stimmel, B., Mehta, D. & Haigney, M.C. QTc interval screening in methadone treatment. Ann. Intern. Med. 150, 387-395 (2009).
18. Krantz, M.J. & Mehler, P.S. Methadone and QT prolongation: a dose-dependent effect? Am. J. Cardiol. 93, 952 (2004). (Pubitemid 38429618)
19. Peles, E., Bodner, G., Kreek, M.J., Rados, V. & Adelson, M. Corrected-QT intervals as related to methadone dose and serum level in methadone maintenance treatment (MMT) patients: a cross-sectional study. Addiction 102, 289-300 (2007). (Pubitemid 46096291)
20. Eap, C.B. et al. Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers. Clin. Pharmacol. Ther. 81, 719-728 (2007). (Pubitemid 46625109)
21. European Medicines Agency. E14: The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs, Questions & Answers (2008).
22. Roden, D.M. Drug-induced prolongation of the QT interval. N. Engl. J. Med. 350, 1013-1022 (2004). (Pubitemid 38269278)
23. Wedam, E.F., Bigelow, G.E., Johnson, R.E., Nuzzo, P.A. & Haigney, M.C. QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch. Intern. Med. 167, 2469-2475 (2007). (Pubitemid 350254906)
24. Wolff, K., Rostami-Hodjegan, A., Hay, A.W., Raistrick, D. & Tucker, G. Populationbased pharmacokinetic approach for methadone monitoring of opiate addicts: potential clinical utility. Addiction 95, 1771-1783 (2000). (Pubitemid 32055815)
25. Foster, D.J., Somogyi, A.A., White, J.M. & Bochner, F. Population pharmacokinetics of (R)-, (S)-and rac-methadone in methadone maintenance patients. Br. J. Clin. Pharmacol. 57, 742-755 (2004). (Pubitemid 38748042)
26. Hanna, J., Foster, D.J., Salter, A., Somogyi, A.A., White, J.M. & Bochner, F. Within-and between-subject variability in methadone pharmacokinetics and pharmacodynamics in methadone maintenance subjects. Br. J. Clin. Pharmacol. 60, 404-413 (2005). (Pubitemid 41428471)
27. Wolff, K. et al. The pharmacokinetics of methadone in healthy subjects and opiate users. Br. J. Clin. Pharmacol. 44, 325-334 (1997). (Pubitemid 27402106)
28. Liu, P., Foster, G., Labadie, R., Somoza, E. & Sharma, A. Pharmacokinetic interaction between voriconazole and methadone at steady state in patients on methadone therapy. Antimicrob. Agents Chemother. 51, 110-118 (2007). (Pubitemid 46047695)
29. Cao, Y.J. et al. Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with fosamprenavir-ritonavir in opioiddependent subjects. Pharmacotherapy 28, 863-874 (2008).
30. Sekar, V. et al. Pharmacokinetic interactions between darunavir/ritonavir and opioid maintenance therapy using methadone or buprenorphine/naloxone. J. Clin. Pharmacol. 51, 271-278 (2011).
31. Sulkowski, M. et al. Peginterferon alfa-2a does not alter the pharmacokinetics of methadone in patients with chronic hepatitis C undergoing methadone maintenance therapy. Clin. Pharmacol. Ther. 77, 214-224 (2005). (Pubitemid 40269136)
32. Bazett, J.C. An analysis of time relations of electrocardiograms. Heart 7, 353-367 (1920).
33. Fridericia, L.S. Die Systolendauer im Elektrokardiogramm bei normalen Menschen und bei Herzkranken. Acta Med Scand 53, 469-486 (1920).
34. Shah, R.R. Cardiac repolarisation and drug regulation: assessing cardiac safety 10 years after the CPMP guidance. Drug Saf. 30, 1093-1110 (2007). (Pubitemid 350172852)
35. Priori, S.G. et al. Risk stratification in the long-QT syndrome. N. Engl. J. Med. 348, 1866-1874 (2003). (Pubitemid 36532312)
36. Straus, S.M. et al. Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. J. Am. Coll. Cardiol. 47, 362-367 (2006). (Pubitemid 43063255)
37. Makkar, R.R., Fromm, B.S., Steinman, R.T., Meissner, M.D. & Lehmann, M.H. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 270, 2590-2597 (1993). (Pubitemid 23346699)
38. Bednar, M.M., Harrigan, E.P. & Ruskin, J.N. Torsades de pointes associated with nonantiarrhythmic drugs and observations on gender and QTc. Am. J. Cardiol. 89, 1316-1319 (2002). (Pubitemid 34606900)
39. Fanoe, S., Hvidt, C., Ege, P. & Jensen, G.B. Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen. Heart 93, 1051-1055 (2007). (Pubitemid 47310981)
40. Cruciani, R.A. et al. Measurement of QTc in patients receiving chronic methadone therapy. J. Pain Symptom Manage. 29, 385-391 (2005). (Pubitemid 40602519)
41. Maremmani, I., Pacini, M., Cesaroni, C., Lovrecic, M., Perugi, G. & Tagliamonte, A. QTc interval prolongation in patients on long-term methadone maintenance therapy. Eur. Addict. Res. 11, 44-49 (2005). (Pubitemid 40082210)
42. Ferreira, S., Crumb, W.J. Jr, Carlton, C.G. & Clarkson, C.W. Effects of cocaine and its major metabolites on the HERG-encoded potassium channel. J. Pharmacol. Exp. Ther. 299, 220-226 (2001). (Pubitemid 32905138)
43. Krantz, M.J., Rowan, S.B. & Mehler, P.S. Cocaine-related torsade de pointes in a methadone maintenance patient. J. Addict. Dis. 24, 53-60 (2005). (Pubitemid 40209081)
44. Bruce, R.D., Kresina, T.F. & McCance-Katz, E.F. Medication-assisted treatment and HIV/AIDS: aspects in treating HIV-infected drug users. AIDS 24, 331-340 (2010).
45. Bertschy, G., Baumann, P., Eap, C.B. & Baettig, D. Probable metabolic interaction between methadone and fluvoxamine in addict patients. Ther. Drug Monit. 16, 42-45 (1994). (Pubitemid 24042311)
46. Kharasch, E.D., Hoffer, C., Whittington, D. & Sheffels, P. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin. Pharmacol. Ther. 76, 250-269 (2004). (Pubitemid 39221799)
47. Wolff, K., Garretty, D. & Hay, A.W. Micro-extraction of commonly abused benzodiazepines for urinary screening by liquid chromatography. Ann. Clin. Biochem. 34 (Pt 1), 61-67 (1997). (Pubitemid 27067870)